Dosing modifications of targeted cancer therapies in patients with special needs: Evidence and controversies

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 1, 2012, Pages 58-74

  Ng, T ^a   Chan, A ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Administration and dosage; Cancer; Drug interactions; Dysfunction; Hepatic; Renal; Smoking

Indexed keywords

ALEMTUZUMAB; ALITRETINOIN; ARSENIC TRIOXIDE; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; CETUXIMAB; DASATINIB; DENILEUKIN DIFTITOX; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMTUZUMAB; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; LENALIDOMIDE; NILOTINIB; PANITUMUMAB; PAZOPANIB; RETINOIC ACID; RITUXIMAB; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG;

CIGARETTE SMOKING; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG WITHDRAWAL; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER METABOLISM; MOLECULARLY TARGETED THERAPY; NEEDS ASSESSMENT; REVIEW; SYSTEMATIC REVIEW;

EID: 84984537308     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.02.006     Document Type: Review

References (119)

1. Institute NC Targeted cancer therapies 2009, National Cancer Institute, Bethesda, MD, Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted [updated 07/29; cited 2009 December 10].
2. Hait W.N. Targeted cancer therapeutics. Cancer Research 2009, 69(4):1263-1267. [review].
3. Bagshawe K.D. The history of targeted therapy for cancer 2003, Oxford University Press, New York, NY.
4. Superfin D., Iannucci A.A., Davies A.M. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. The Oncologist 2007, 12:1070-1083.
5. Verbeeck R.K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. European Journal of Clinical Pharmacology 2008, 64:1147-1161. [review].
6. Verbeeck R.K., Musuamba F.T. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. European Journal of Clinical Pharmacology 2009, 65:757-773. [review].
7. Zevin S., Neal L.B. Drug interactions with tobacco smoking. An update. Clinical Pharmacokinetics 1999, 36(6):425-438. [abstract].
8. Donelli M.G., Zucchetti M., Munzone E., D'Incalci M., Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. European Journal of Cancer 1998, 34(1):33-46.
9. Vidal L., Shavit M., Fraser A., Paul M., Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005, 331:263-266.
10. Polen H.H., Zapantis A., Clauson K.A., Jebrock J., Paris M. Ability of online drug databases to assist in clinical decision-making with infectious disease therapies. BMC Infectious Diseases 2008, 8:153.
11. Wong C.-M., Ko Y., Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents:profiling and comparison of two drug compendia. The Annals of Pharmacotherapy 2008, 42:1737-1748.
12. Somerfield M., Padberg J., Pfister D., et al. ASCO clinical practice guidelines: process, progress, pitfalls, and prospects. Classic Papers Current Comments 2000, 4:881-886.
13. Saif M.W. Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder. JOP: Journal of the Pancreas 2008, 9(6):748-752.
14. ZOLINZA (vorinostat) 2009, MERCK & CO. INC., Whitehouse Station, NJ.
15. Panretin (alitretinoin) 1999, Ligand Pharmaceuticals Incorporated, San Diego, CA.
16. Targretin (bexarotene) 2003, Ligand Pharmaceuticals Incorporated, San Diego, CA.
17. Campath (alemtuzumab) 2007, Genzyme Corporation, Cambridge, MA.
18. AVASTIN (bevacizumab) 2009, Genentech, Inc., South San Francisco, CA.
19. Shen B.-Q., Li D., Oldendorp A., et al. Hepatic dysfunction resulting from common bile duct ligation (BDL) did not affect the pharmacokinetics of bevacizumab (Avastin) in Sprague-Dawley rats. Proceedings of the American Association for Cancer Research 2006, 47. Abstract No. 3106.
20. Leveque D., Gigou L., Bergerat J.P. Clinical pharmacology of trastuzumab. Current Clinical Pharmacology 2008, 3(1):51-55.
21. Qazilbash M.H., Qu Z., Hosing C., et al. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. American Journal of Hematology 2005, 80:43-45.
22. Kell W.J., Burnett A.K., Chopra R., et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003, 102(13):4277-4283.
23. Niu C., Yan H., Yu T., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94(November (10)):3315-3324.
24. Wiseman G.A., White C.A., Stabin M., et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European Journal of Nuclear Medicine 2000, 27(July (7)):766-777.
25. TYKERB (lapatinib) 2010, GlaxoSmithKline, Research Triangle Park, NC.
26. IRESSA (gefitinib) 2004, AstraZeneca Pharmaceuticals LP, Wilmington, DE.
27. The pharmacokinetics and tolerability of ZD1839 ('Iressa') in hepatically impaired patients with solid tumours. 38th annual meeting of the American Society of Clinical Oncology 2002, C. Twelves, J. White, A. Harris (Eds.).
28. Kim Y.H., Mio T., Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis. Internal Medicine (Tokyo, Japan) 2009, 48(18):1677-1679.
29. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics 1981, 30(August (2)):239-245.
30. Launay-Vacher V., Oudard S., Janus N., et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007, 110(September (6)):1376-1384.
31. SPRYCEL (dasatinib) 2009, Bristol-Myers Squibb Company, Princeton, NJ.
32. Wong S.F. New dosing schedules of dasatinib for CML and adverse event management. Journal of Hematology & Oncology 2009, 2(10):10.
33. Polli J.W., Humphreys J.E., Harmon K.A., et al. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metabolism and Disposition 2008, 36(4):695-701.
34. AFINITOR (everolimus) 2009, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
35. Carles J., Morales R., Perez JeM, Suóarez C., Rodóon J., Valverde C. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities. European Journal of Cancer 2009, 45:309-317.
36. Fujiwara Y., Yamamoto N., Yamada Y., et al. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Science 2009, 100(September (9)):1728-1734.
37. BEXXAR (Tositumomab, Iodine 1131 Tositumomab) 2004, Corixa Corp and GlaxoSmithKline, Seattle, WA.
38. van Erp N., Gelderblom H., van Glabbeke M., et al. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. Clinical Cancer Research 2008, 14(December (24)):8308-8313.
39. Hughes A.N., O'Brien M.E., Petty W.J., et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. Journal of Clinical Oncology 2009, 27(March (8)):1220-1226.
40. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clinical Cancer Research 2007, 13(June (12)):3731-3737.
41. TARCEVA (erlotinib) 2009, OSI Pharmaceuticals Inc., Melville, NY.
42. Vincenzi B., Santini D., Loupakis F., et al. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opinion on Biological Therapy 2009, 9(8):945-949.
43. Lam M.S., Ignoffo R.J. A guide to clinically relevant drug interactions in oncology. Journal of Oncology Pharmacy Practice 2003, 9(2-3):45-85.
44. Ogu C.C., Maxa J.L. Drug interactions due to cytochrome P450. Proceedings (Bayl Univ Med Cent) 2000, 13(4):421-423.
45. TRISENOX (arsenic trioxide) 2000, Cell Therapeutics, Inc., Seattle, WA.
46. ISTODAX (romidepsin) 2009, Gloucester Pharmaceuticals, Inc., Cambridge, MA.
47. Shiraga T., Tozuka Z., Ishimura R., Kawamura A., Kagayama A. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biological & Pharmaceutical Bulletin 2005, 28(January (1)):124-129.
48. Dutreix C., Peng B., Mehring G., et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemotherapy and Pharmacology 2004, 54:290-294.
49. van Erp N.P., Gelderblom H., Karlsson M.O., et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clinical Cancer Research 2007, 13(December (24)):7394-7400.
50. Gibbons J., Egorin M.J., Ramanathan R.K., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology 2008, 26(February (4)):570-576.
51. Ramanathan R.K., Egorin M.J., Takimoto C.H.M., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology 2008, 26(4):570-576.
52. Patel H., Egorin M., Remick S., et al. Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing. Proceedings of the American Society of Clinical Oncology 2004, 22:6051.
53. Elter T., Molnar I., Kuhlmann J., Hallek M., Wendtner C. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leukemia & Lymphoma 2008, 49(12):2256-2262.
54. Haslbauer F. A case report of successful alemtuzumab treatment of a B-CLL patient suffering from renal failure. Annals of Hematology 2009, 88(4):399-400.
55. Au W.Y., Kwong Y.L. Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 2008, 29(3):296-304.
56. Kwong Y.L. Arsenic trioxide in the treatment of haematological malignancies. Expert Opinion on Drug Safety 2004, 3(November (6)):589-597.
57. VELCADE (bortezomib) 2009, Millennium Pharmaceuticals Inc., Cambridge, MA.
58. San-Miguel J., Richardson P., Sonneveld P., et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia Research 2008, 22(4):842-849.
59. Chanan-Khan A.A., Kaufman J.L., Mehta J., et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007, 109(6):2604-2606.
60. Garnier-Viougeat N., Rixe O., Paintaud G., et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrology, Dialysis, Transplantation 2007, 22(3):975.
61. Zhu A.X., Stuart K., Blaszkowsky L.S., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110(3):581-589.
62. A population pharmacokinetic (PPK) analysis of the anti-EGFr specific IgG1 monoclonal antibody cetuximab. Gastrointestinal Cancers Symposium 2004, F.E. Fox, D. Mauro, S. Bai (Eds.).
63. Thariat J., Azzopardi N., Peyrade F., et al. Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. Journal of Clinical Oncology 2008, 26(25):4223-4225.
64. Olsen E., Duvic M., Frankel A., et al. Pivotal phase iii trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology 2001, 19(2):376-388.
65. Kovarik J., Sabia H., Figueiredo J., et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clinical Pharmacology and Therapeutics 2001, 70(5):425-430. [abstract].
66. Kirchner G.I., Meier-Wiedenbach I., Manns M.P. Clinical pharmacokinetics of everolimus. Clinical Pharmacokinetics 2004, 43(2):83-95.
67. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Journal of Clinical Oncology 2007, 25(21):3055-3060.
68. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clinical Therapeutics 2005, 27(10):1513-1534.
69. TARCEVA (erlotinib) 2010, OSI Pharmaceuticals Inc., Melville, NY.
70. Shinagawa N., Yamazaki K., Asahina H., Agata J., Itoh T., Nishimura M. Gefitinib administration in a patient with lung cancer undergoing hemodialysis. Lung Cancer 2007, 58(December (3)):422-424.
71. Rossia A., Maionea P., Gaizoa F.D., Guerrieroa C., Castaldob V., Gridellia C. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005, 47(3):421-423.
72. Case report of gemtuzumab ozogamicin administered to a patient on hemodialysis. 38th annual meeting of the American Society of Clinical Oncology 2002, E. Stuntebeck, J. Essell, M. DeVoe (Eds.).
73. GLEEVEC (imatinib mesylate) 2009, Novartis Pharmaceuticals Corporation, East Hanover, NJ.
74. REVLIMID (lenalidomide) 2009, Celgene Corporation, Summit, NJ.
75. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Journal of Clinical Oncology 2007, 47(12):1466-1475.
76. Caki{dotless}r A., Demirel B. A software tool for determination of breast cancer treatment methods using data mining approach. Journal of Medical Systems 2010, [Epub].
77. Deininger M. Nilotinib. Clinical Cancer Research 2008, 14(13):4027-4031.
78. VOTRIENT (pazopanib) 2009, GlaxoSmithKline, Research Triangle Park, NC.
79. Vectibix (panitumumab) 2009, Amgen Inc., Thousand Oaks, CA.
80. Jillella A.P., Dainer P.M., Kallab A.M., Ustun C. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis. American Journal of Hematology 2002, 71(3):219-222.
81. Tokar M., Rogachev B., Levi I., Yerushalmi R., Ariad S., Geffen D. Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys. Leukemia & Lymphoma 2004, 45(4):819-820. [abstract].
82. Abdelkefi A., Mellouli F., Bejaoui M. Treatment of a patient with chronic renal failure with rituximab for a follicular lymphoma: safe and successful option of rituximab therapy. European Journal of Haematology 2003, 71(August (2)):128-129.
83. SUTENT (sunitinib malate) 2006, Pfizer Inc., New York, NY.
84. Bello C.L., Garrett M., Smeraglia J., Sherman L., Ryan B., Toh M. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemotherapy and Pharmacology 2009, December 9 [E-pub ahead of print]. 10.1007/s00280-009-1213-4.
85. Izzedine H., Etienne-Grimaldi M.C., Renee N., Vignot S., Milano G. Pharmacokinetics of sunitinib in hemodialysis. Annals of Oncology 2009, 20(1):190-192.
86. Lainakis G., Bamias A., Psimenou E., Fountzilas G.M.A.D. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the hellenic cooperative oncology group. Clinical Nephrology 2009, 72(1):73-78. [abstract].
87. Miller A.A., Murry D.J., Owzar K., et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology 2009, 27(11):1800-1805.
88. THALOMID (thalidomide) 2006, Celgene Corporation, Summit, NJ.
89. Shiah H.-S., Chao Y., Chen L.-T., et al. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 2006, 58(5):654-664. [abstract].
90. Lepper E., Smith N., Cox M., Scripture C., Figg W. Thalidomide metabolism and hydrolysis: mechanisms and implications. Current Drug Metabolism 2006, 7(6):677-685. [abstract].
91. Eriksson T., Höglund P., Turesson I., et al. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. Journal of Pharmacy and Pharmacology 2003, 55(12):1701-1706.
92. Arai A., Hirota A., Fukuda T., et al. Analysis of plasma concentration of thalidomide in Japanese patients of multiple myeloma with renal dysfunction. [Rinshō ketsueki] The Japanese Journal of Clinical Hematology 2009, 50(4):295-299. [abstract].
93. Tosi P., Zamagni E., Cellini C., et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. European Journal of Haematology 2004, 73(2):98-103. [abstract].
94. VESANOID (tretinoin) 2008, Roche Laboratories Inc., Nutley, NJ.
95. Yamane A., Tsukamoto N., Saitoh T., et al. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Internal Medicine (Tokyo, Japan) 2009, 48(18):1691-1694.
96. De Botton S., Dombret H., Sanz M., et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998, 92(8):2712-2718.
97. Matsumoto K., Tamaki H., Yamagami T., Sasaki N., Hara S., Soma T. Successful remission induction by low-dose all-trans retinoic acid alone in a patient with acute promyelocytic leukemia and renal impairment. Leukemia Research 2008, 32(March (3)):512-514.
98. HERCEPTIN (trastuzumab) 2008, Genentech, Inc., South San Francisco, CA.
99. Micallef R., Barrett-Lee P., Donovan K., Ashraf M., Williams L. Trastuzumab in patients on haemodialysis for renal failure. Clinical Oncology: A Journal of the Royal College of Radiologists 2007, 19(7):559.
100. TORISEL Kit (temsirolimus) 2008, Wyeth Pharmaceuticals Inc., Philadelphia, PA.
101. Lunardi G., Armirotti A., Nicodemo M., et al. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Clinical Therapeutics 2009, 31(8):1812-1819. [abstract].
102. Hamilton M., Wolf J.L., Rusk J., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clinical Cancer Research 2006, 12(April (7 Pt 1)):2166-2171.
103. Yamamoto N., Horiike A., Fujisaka Y., et al. Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology 2008, 61(March (3)):489-496.
104. Lu J.F., Eppler S.M., Wolf J., et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clinical Pharmacology & Therapeutics 2006, 80(August (2)):136-145.
105. Smith D.A., Koch K.M., Arya N., Bowen C.J., Herendeen J.M., Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology 2009, 67(April (4)):421-426.
106. Deremer D.L., Ustun C., Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics 2008, 30(November (11)):1956-1975.
107. NEXAVAR (sorafenib) 2007, Bayer Pharmaceuticals Corporation, West Haven, CT.
108. Teo S.K., Scheffler M.R., Kook K.A., et al. Thalidomide dose proportionality assessment following single doses to healthy subjects. Journal of Clinical Pharmacology 2001, 41(June (6)):662-667.
109. Venkatakrishnan K., Rader M., Ramanathan R.K., et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clinical Therapeutics 2009, 31(Pt 2):2444-2458.
110. Kovarik J.M., Hartmann S., Figueiredo J., Rouilly M., Port A., Rordorf C. Effect of rifampin on apparent clearance of everolimus. The Annals of Pharmacotherapy 2002, 36(June (6)):981-985. [abstract].
111. Kovarik J.M., Beyer D., Schmouder R.L. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharmaceutics & Drug Disposition 2006, 27(December (9)):421-426.
112. Kovarik J.M., Beyer D., Bizot M.N., Jiang Q., Shenouda M., Schmouder R.L. Blood concentrations of everolimus are markedly increased by ketoconazole. Journal of Clinical Pharmacology 2005, 45(May (5)):514-518.
113. Swaisland H.C., Ranson M., Smith R.P., et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clinical Pharmacokinetics 2005, 44(10):1067-1081. [abstract].
114. Frye R.F., Fitzgerald S.M., Lagattuta T.F., Hruska M.W., Egorin M.J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clinical Pharmacology and Therapeutics 2004, 76(October (4)):323-329.
115. Hazarika M., Jiang X., Liu Q., et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clinical Cancer Research 2008, 14(17):5325-5331.
116. Boni J., Leister C., Burns J., Cincotta M., Hug B., Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. Journal of Clinical Pharmacology 2007, 47(November (11)):1430-1439.
117. Boni J.P., Leister C., Burns J., Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. British Journal of Cancer 2008, 98(June (11)):1797-1802.
118. McSorley L.C., Daly A.K. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochemical Pharmacology 2000, 60(4):517-526.
119. Bennett M.T., Sirrs S., Yeung J.K., Smith C.A. Hypercalcemia due to all trans retinoic acid in the treatment of acute promyelocytic leukemia potentiated by voriconazole. Leukemia & Lymphoma 2005, 46(12):1829-1831.